Latest Toron Inc (TRON) Headlines Trion Worlds An
Post# of 178
Posted On: 03/11/2014 9:08:41 PM
Latest Toron Inc (TRON) Headlines
Trion Worlds Announces Glyph Digital Games Platform
Business Wire - Tue Mar 11, 11:00AM CDT
Trion Worlds, global developer and publisher of premium online games, has officially announced Glyph, a new lightweight digital hub for PC games and their digital goods. Glyph will introduce the more than 10 million players that have signed on with Trion Worlds to a curated collection of quality games, including Trion titles as well as games from hand-picked partners.
Concise Analysis of the International Bispecific Antibody Therapeutics Market
M2 - Tue Mar 04, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/c63zqb/bispecific) has announced the addition of the "Concise Analysis of the International Bispecific Antibody Therapeutics Market" report to their offering. Antibody based therapeutics are the fastest growing segment of the drugs and biologics market. There are 30 approved antibody based therapeutics available in the US and European markets since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986. A bispecific antibody is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality. The conjugated artificial antibodies are formed by physically putting together two monoclonal antibodies (or parts of) which have different binding specificities. This results in a combination antibody that has simultaneous functional binding affinities to two or three different epitopes. The combination may have additive and sometimes even a synergistic effect in combating a disease. With the EMA approval for Removab in 2009, a great deal of interest has been generated in the bispecific antibody market. The pipeline is rich and diverse, with drugs being developed for both oncological and non-oncological indications. The industry has drugs in phase I and phase II of clinical trials but currently lacks drugs in phase III. The Bispecific Antibody Therapeutics Market, 2013-2023 report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously. Key Topics Covered: 1. EXECUTIVE SUMMARY 2. INTRODUCTION 3. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES 4. CURRENT MARKET AND FORECAST 5. TECHNOLOGY PLATFORMS 6. PROFILES OF LEADING COMPANIES 7. SWOT ANALYSIS 8. CONCLUSIONS 9. LIST OF COMPANIES AND ORGANISATIONS 10. TABLES Companies Mentioned: - Abbvie - Ablynx - BMS - Boehringer Ingelheim - Celgene - Chiome Bioscience - Chromacon - Chugai - Covagen - Dow Pharma - Dutalys - EMD Serono - Eli Lilly - Emergent - Epigen Biotech - Fabion Pharmaceuticals - GSK - Imclone Systems - Mitsubishi Tanabe - Molecular Partners AG - Novartis - Novimmune - Numab - OcellO - Oncomed - OtSuka Pharma - Paktis Antibody Services GmbH - Pfizer - Synimmune - Tanabe Research Labs - Trion - UCB-Celltech - X-Body Biosciences - Xencor - Zymeworks - Zymogenetics - Zyngenia For more information visit http://www.researchandmarkets.com/research/c63zqb/bispecific
Research and Markets: Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating
Business Wire - Mon Mar 03, 11:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/cz4wj5/global) has announced the addition of the "Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating" report to their offering.
Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating
M2 - Mon Mar 03, 10:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/bm4r24/global) has announced the addition of the "Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating" report to their offering. Since the Global Electrostatic Precipitator market is highly competitive, manufacturers are providing new and innovative solutions and exploring new application areas for the existing range of products to stay ahead of the competition. Moreover, growing environmental and health concerns have led vendors to focus on the development of products that have higher efficiency and lower power consumption. There is increased expenditure in the market on the R&D of new products and services. More research is being undertaken on upgrading and optimizing the performance of electrostatic precipitators used in different industries. The growth of the Global Electrostatic Precipitator market is driven by several factors, the most important of which is the increase in demand from the APAC region. The growth of the market in this region is positively influenced by government policies to reduce the emissions associated with coal-fired power generation. Further, the report states that one of the key challenges in this market is the growing popularity of fabric filters over electrostatic precipitators. The key vendors dominating this market space are: - Alstom SA - Blacke-Durr GmbH - The Babcock & Wilcox Co. - Trion Inc. Other vendors mentioned in the report are: - Clean Tunnel Air International AS - Siemens AG - Total Air Pollution Control Pty Ltd. For more information visit http://www.researchandmarkets.com/research/bm4r24/global
Crawford Advisors Expands Account Management Team with Raymond Daniels and Leanna Krug
PRWeb - Wed Feb 19, 3:08AM CST
Crawford Advisors, LLC, one of its region's largest full-service benefits and consulting brokerage firms, serving businesses across America, today announced that Raymond Daniels has assumed the position of account manager and Leanna Krug has been appointed assistant accounts manager.
Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
M2 - Mon Feb 17, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/xx9pc7/competitor) has announced the addition of the Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors report to their offering. The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world's commercially most successful antibodies (2013 sales of over US$ 7.7 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Sales of rituximab for treatment of rheumatoid athritis makes out 17.1% of total Rituxan (US) / MabThera (EU) sales.Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies as a measure to protect against emerging rituximab biosimilars. In fact, second generation anti-CD20 antibody Gazyva has already been approved and launched in ist first indication. The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in off-patent countries, but also in phase III studies in Western regulated markets. The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Key Topics Covered: 1. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors Marketed CD20 Antibodies & Sales - Rituxan/MabThera Pipeline & Sales - Arzerra Pipeline & Sales - Gazyva Pipeline & Sales - Bexxar & Zevalin Pipeline & Sales Biosuperior CD20 Antibodies Biosimilar CD20 Antibodies - Rituxan/MabThera (rituximab) Biosimilars - Arzerra (ofatumumab) Biosimilars 2. Corporate CD20 Antibody Biosimilar & Biobetter Pipelines Companies Mentioned: - Actavis (Watson Pharmaceuticals) - Alopexx Oncology - Amgen - Aprogen - Competitor Analysis - Innovent Biologics - Intas Pharmaceuticals - Lentigen - LG Life Sciences - Libbs Farmaceutica - Mabxience - Mentrik Biotech - Merck - Molecular Templates - Natco Pharma - Nichi-Iko Pharmaceutical - Oncobiologics - PanGenerika - PanPharmaceuticals USA - Pfizer - PharmaPraxis - PlantForm - Probiomed - rEVO Biologics - Roche - Sandoz (Novartis) - Shanghai CP Guojian Pharmaceutical Co - Shanghai Henliu Biopharmaceuticals - Spectrum Pharmaceuticals - STADA Arzneimittel 68 - TG Therapeutics - Therapeutics Protein International (TPI) - TRION Pharma - Vaccinex - Valor Biotherapeutics - Viropro - Zhejiang Huahai Pharmaceutical Co For more information visit http://www.researchandmarkets.com/research/xx9pc7/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Trion IAQ Expands its IAQ Line with a New Disposable Filter Program
PRWeb - Tue Feb 04, 7:08AM CST
Trion(R), an innovative, international company dedicated to providing quality products for the commercial, industrial, and residential markets since 1947, announced today its expansion of their residential air filtration line of products. The Trion Residential Disposable Filter Program includes pleated, polyester, and fiberglass disposable filters. Trion strives to continue offering its loyal and potential customers a complete line of indoor air quality solutions.
48th Annual Holiday Boutique Raised $340,000 to Benefit Programs at The Children's Hospital of Philadelphia (CHOP)
PRWeb - Fri Dec 20, 5:46PM CST
The Children's Hospital of Philadelphia's Women's Committee hosted its 48th annual Holiday Boutique at the Merion Cricket Club in Haverford, PA to support patient care, research, and education at the Hospital. More than 700 people attended the Boutique, which included 25 vendors from around the country selling their finest merchandise. Twenty-five percent of vendor sales and other event proceeds benefitted CHOP, raising $340,000 to support patient care, research and education at CHOP through the Women's Committee grants.
Ovarian Cancer - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Ovarian Cancer
M2 - Wed Nov 06, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/2rp465/ovarian_cancer) has announced the addition of the "Ovarian Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Ovarian Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. Ovarian Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Ovarian Cancer. - A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ovarian Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Novartis AG - Samyang Corporation - Aphios Corporation - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - AntiCancer, Inc. - Merck KGaA - Access Pharmaceuticals, Inc. - Advaxis, Inc. - Innocell Corporation - PharmaGap Inc. - TRION Pharma GmbH - Advantagene, Inc. - BioNumerik Pharmaceuticals, Inc. - Alethia Biotherapeutics Inc. - OnKor Pharmaceuticals, Inc. - Coronado Biosciences, Inc. - Cerulean Pharma, Inc. - Heat Biologics, Inc. - PepTx, Inc. - Mebiopharm Co., Ltd. - DEKK-TEC, Inc. - ISA Pharmaceuticals B.V. - TAU Therapeutics, LLC - Gradalis Inc. For more information visit http://www.researchandmarkets.com/research/2r...ian_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Filtration.com Now Carries Trion Air Bear(R) Furnace Filters
PRWeb - Wed Sep 18, 9:31AM CDT
Filtration.com, a premier indoor air quality online store is proud to announce the newest addition to their product line, Trion Air Bear(R) filters. Trion is an aftermarket media air filter that fits in models from Generalaire(R), Skuttle(R), Ultravation(R) and their own Trion air purification system - Trion Air Bear Cub Air Cleaner.
Peritoneal Cancer - Pipeline Review, H2 2013 Report will Assist you in Planning Mergers and Acquisitions Effectively by Identifying Players of the Most Promising Pipeline
M2 - Mon Aug 12, 10:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zgbb5m/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Peritoneal Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peritoneal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peritoneal Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Peritoneal Cancer. - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Peritoneal Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: AstraZeneca PLC GlaxoSmithKline plc Oxford BioMedica plc Millennium Pharmaceuticals, Inc. Novartis AG Bayer AG Incyte Corporation EntreMed, Inc. Oncolytics Biotech Inc. Synta Pharmaceuticals Corp. Oasmia Pharmaceutical AB Spectrum Pharmaceuticals, Inc. Acceleron Pharma, Inc. TRION Pharma GmbH TetraLogic Pharmaceuticals CritiTech, Inc. ImmunoVaccine Technologies Inc. VentiRx Pharmaceuticals, Inc. Genelux Corporation For more information visit http://www.researchandmarkets.com/research/zg...eal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Fallopian Tube Cancer - Pipeline Review, H2 2013: Plan Mergers and Acquisitions Effectively By Identifying Players
M2 - Fri Aug 09, 6:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7fs44g/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Fallopian Tube Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer. Scope - A snapshot of the global therapeutic scenario for Fallopian Tube Cancer. - A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fallopian Tube Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 - Acceleron Pharma, Inc. - Amgen Inc. - AstraZeneca PLC - Boehringer Ingelheim GmbH - Cell Therapeutics, Inc. - Daiichi Sankyo Company, Ltd - Eli Lilly and Company - EntreMed, Inc. - GlaxoSmithKline plc - ImmunoVaccine Technologies Inc. - Incyte Corporation - Marshall Edwards, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - Oncolytics Biotech Inc. - Oxford BioMedica plc - RECEPTA Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRACON Pharmaceuticals, Inc. - TRION Pharma GmbH - TetraLogic Pharmaceuticals - VentiRx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/7f...lopian_tub About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epithelial Ovarian Cancer - Latest Pipeline Review Report
M2 - Wed Aug 07, 8:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/62k5jl/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H2 2013" report to their offering. 'Epithelial Ovarian Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epithelial Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer. Scope - A snapshot of the global therapeutic scenario for Epithelial Ovarian Cancer. - A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epithelial Ovarian Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Epithelial Ovarian Cancer Therapeutics Development - Boehringer Ingelheim GmbH - Amgen Inc. - AstraZeneca PLC - Oxford BioMedica plc - Novartis AG - Astellas Pharma Inc. - Bayer AG - Prima BioMed Limited - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - TRION Pharma GmbH - BioNumerik Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - RECEPTA Biopharma S.A. Drug Profiles - trebananib - sorafenib tosylate - elesclomol - paclitaxel - TroVax - MEK-162 - nintedanib - catumaxomab - CVac - VTX-2337 - levonorgestrel - plevitrexed - RebmAb-100 - cositecan - EGEN-001 - NY-ESO-1 Overlapping Peptides Vaccine - Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - HER-2/Neu Specific T Cells - MV-NIS Vaccine - pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine - Globo-H-GM2-sTn-TF-Tn-KLH Conjugate [QS-21] - DCVAC/OvCa For more information visit http://www.researchandmarkets.com/research/62k5jl/epithelial
Trion(R) Introduces a Motorized Air Damper for the Residential Market
PRWeb - Tue Aug 06, 8:07AM CDT
Trion(R), an innovative, international company dedicated to providing quality products for the commercial, industrial, and residential markets since 1947, is proud to introduce the latest product offering in residential indoor air quality. The Trion Motorized Damper (TMD520) is designed to introduce fresh air into the building envelope through an intake damper that is controlled by the microprocessor-based ventilation control interface. The system controls the amount of outdoor ventilation, promoting healthier indoor air quality, required by the Ventilation and Air Quality Standard defined in ASHRAE 62.2. This standard defines the roles of, and minimum requirements for, mechanical and natural ventilation systems and the building envelope intended to provide acceptable indoor air quality (IAQ) in low-rise residential buildings.
Game Industry Veteran Robin Kaminsky Joins Trion Worlds' Board of Directors
Business Wire - Thu Jul 11, 12:02PM CDT
Trion Worlds, global developer and publisher of premium online games, has brought technology, video games and entertainment executive Robin Kaminsky onto the company's Board of Directors.
Trion(R) Introduces the Latest Solution in Commercial Kitchen Air Cleaning
PRWeb - Thu May 16, 7:05AM CDT
Trion(R), an innovative, international company dedicated to providing quality indoor air quality products for the commercial, industrial, and residential markets since 1947, is proud to introduce the latest innovation in commercial indoor air quality. The Grease Viper(TM) Commercial Kitchen Air Cleaner is designed to treat grease, smoke, and odor emissions from exhaust ducts on commercial cooking applications.
Defiance(TM) Launches Worldwide Today
Business Wire - Tue Apr 02, 10:00AM CDT
Trion Worlds, the leading publisher and developer of premium games for the connected era, is proud to announce the launch of Defiance(TM), the groundbreaking futuristic online open world shooter for the Xbox 360(R) video game and entertainment system, the PlayStation(R)3 computer entertainment system and Windows PC. The Defiance Universe expands even further on April 15th, with the premiere of Syfy Network's Defiance series.
Trion Worlds and XLGAMES Team up to Bring Highly Anticipated ArcheAge(R) to Western Markets
Business Wire - Thu Jan 24, 12:00PM CST
Leading online games company Trion Worlds and renowned South Korea-based game developer XLGAMES have entered into a strategic agreement for Trion to exclusively publish and operate ArcheAge(R) in the West. Created by Jake Song, best known for his hit game Lineage, the highly anticipated ArcheAge is poised to be the most polished massively multiplayer online role-playing game (MMORPG) coming out of Asia. Trion will host the game on its Red Door platform in North America, Europe, Turkey, Australia and New Zealand.
Trion Worlds Announces Glyph Digital Games Platform
Business Wire - Tue Mar 11, 11:00AM CDT
Trion Worlds, global developer and publisher of premium online games, has officially announced Glyph, a new lightweight digital hub for PC games and their digital goods. Glyph will introduce the more than 10 million players that have signed on with Trion Worlds to a curated collection of quality games, including Trion titles as well as games from hand-picked partners.
Concise Analysis of the International Bispecific Antibody Therapeutics Market
M2 - Tue Mar 04, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/c63zqb/bispecific) has announced the addition of the "Concise Analysis of the International Bispecific Antibody Therapeutics Market" report to their offering. Antibody based therapeutics are the fastest growing segment of the drugs and biologics market. There are 30 approved antibody based therapeutics available in the US and European markets since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986. A bispecific antibody is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality. The conjugated artificial antibodies are formed by physically putting together two monoclonal antibodies (or parts of) which have different binding specificities. This results in a combination antibody that has simultaneous functional binding affinities to two or three different epitopes. The combination may have additive and sometimes even a synergistic effect in combating a disease. With the EMA approval for Removab in 2009, a great deal of interest has been generated in the bispecific antibody market. The pipeline is rich and diverse, with drugs being developed for both oncological and non-oncological indications. The industry has drugs in phase I and phase II of clinical trials but currently lacks drugs in phase III. The Bispecific Antibody Therapeutics Market, 2013-2023 report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously. Key Topics Covered: 1. EXECUTIVE SUMMARY 2. INTRODUCTION 3. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES 4. CURRENT MARKET AND FORECAST 5. TECHNOLOGY PLATFORMS 6. PROFILES OF LEADING COMPANIES 7. SWOT ANALYSIS 8. CONCLUSIONS 9. LIST OF COMPANIES AND ORGANISATIONS 10. TABLES Companies Mentioned: - Abbvie - Ablynx - BMS - Boehringer Ingelheim - Celgene - Chiome Bioscience - Chromacon - Chugai - Covagen - Dow Pharma - Dutalys - EMD Serono - Eli Lilly - Emergent - Epigen Biotech - Fabion Pharmaceuticals - GSK - Imclone Systems - Mitsubishi Tanabe - Molecular Partners AG - Novartis - Novimmune - Numab - OcellO - Oncomed - OtSuka Pharma - Paktis Antibody Services GmbH - Pfizer - Synimmune - Tanabe Research Labs - Trion - UCB-Celltech - X-Body Biosciences - Xencor - Zymeworks - Zymogenetics - Zyngenia For more information visit http://www.researchandmarkets.com/research/c63zqb/bispecific
Research and Markets: Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating
Business Wire - Mon Mar 03, 11:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/cz4wj5/global) has announced the addition of the "Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating" report to their offering.
Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating
M2 - Mon Mar 03, 10:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/bm4r24/global) has announced the addition of the "Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating" report to their offering. Since the Global Electrostatic Precipitator market is highly competitive, manufacturers are providing new and innovative solutions and exploring new application areas for the existing range of products to stay ahead of the competition. Moreover, growing environmental and health concerns have led vendors to focus on the development of products that have higher efficiency and lower power consumption. There is increased expenditure in the market on the R&D of new products and services. More research is being undertaken on upgrading and optimizing the performance of electrostatic precipitators used in different industries. The growth of the Global Electrostatic Precipitator market is driven by several factors, the most important of which is the increase in demand from the APAC region. The growth of the market in this region is positively influenced by government policies to reduce the emissions associated with coal-fired power generation. Further, the report states that one of the key challenges in this market is the growing popularity of fabric filters over electrostatic precipitators. The key vendors dominating this market space are: - Alstom SA - Blacke-Durr GmbH - The Babcock & Wilcox Co. - Trion Inc. Other vendors mentioned in the report are: - Clean Tunnel Air International AS - Siemens AG - Total Air Pollution Control Pty Ltd. For more information visit http://www.researchandmarkets.com/research/bm4r24/global
Crawford Advisors Expands Account Management Team with Raymond Daniels and Leanna Krug
PRWeb - Wed Feb 19, 3:08AM CST
Crawford Advisors, LLC, one of its region's largest full-service benefits and consulting brokerage firms, serving businesses across America, today announced that Raymond Daniels has assumed the position of account manager and Leanna Krug has been appointed assistant accounts manager.
Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
M2 - Mon Feb 17, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/xx9pc7/competitor) has announced the addition of the Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors report to their offering. The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world's commercially most successful antibodies (2013 sales of over US$ 7.7 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Sales of rituximab for treatment of rheumatoid athritis makes out 17.1% of total Rituxan (US) / MabThera (EU) sales.Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies as a measure to protect against emerging rituximab biosimilars. In fact, second generation anti-CD20 antibody Gazyva has already been approved and launched in ist first indication. The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in off-patent countries, but also in phase III studies in Western regulated markets. The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Key Topics Covered: 1. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors Marketed CD20 Antibodies & Sales - Rituxan/MabThera Pipeline & Sales - Arzerra Pipeline & Sales - Gazyva Pipeline & Sales - Bexxar & Zevalin Pipeline & Sales Biosuperior CD20 Antibodies Biosimilar CD20 Antibodies - Rituxan/MabThera (rituximab) Biosimilars - Arzerra (ofatumumab) Biosimilars 2. Corporate CD20 Antibody Biosimilar & Biobetter Pipelines Companies Mentioned: - Actavis (Watson Pharmaceuticals) - Alopexx Oncology - Amgen - Aprogen - Competitor Analysis - Innovent Biologics - Intas Pharmaceuticals - Lentigen - LG Life Sciences - Libbs Farmaceutica - Mabxience - Mentrik Biotech - Merck - Molecular Templates - Natco Pharma - Nichi-Iko Pharmaceutical - Oncobiologics - PanGenerika - PanPharmaceuticals USA - Pfizer - PharmaPraxis - PlantForm - Probiomed - rEVO Biologics - Roche - Sandoz (Novartis) - Shanghai CP Guojian Pharmaceutical Co - Shanghai Henliu Biopharmaceuticals - Spectrum Pharmaceuticals - STADA Arzneimittel 68 - TG Therapeutics - Therapeutics Protein International (TPI) - TRION Pharma - Vaccinex - Valor Biotherapeutics - Viropro - Zhejiang Huahai Pharmaceutical Co For more information visit http://www.researchandmarkets.com/research/xx9pc7/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Trion IAQ Expands its IAQ Line with a New Disposable Filter Program
PRWeb - Tue Feb 04, 7:08AM CST
Trion(R), an innovative, international company dedicated to providing quality products for the commercial, industrial, and residential markets since 1947, announced today its expansion of their residential air filtration line of products. The Trion Residential Disposable Filter Program includes pleated, polyester, and fiberglass disposable filters. Trion strives to continue offering its loyal and potential customers a complete line of indoor air quality solutions.
48th Annual Holiday Boutique Raised $340,000 to Benefit Programs at The Children's Hospital of Philadelphia (CHOP)
PRWeb - Fri Dec 20, 5:46PM CST
The Children's Hospital of Philadelphia's Women's Committee hosted its 48th annual Holiday Boutique at the Merion Cricket Club in Haverford, PA to support patient care, research, and education at the Hospital. More than 700 people attended the Boutique, which included 25 vendors from around the country selling their finest merchandise. Twenty-five percent of vendor sales and other event proceeds benefitted CHOP, raising $340,000 to support patient care, research and education at CHOP through the Women's Committee grants.
Ovarian Cancer - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Ovarian Cancer
M2 - Wed Nov 06, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/2rp465/ovarian_cancer) has announced the addition of the "Ovarian Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Ovarian Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. Ovarian Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Ovarian Cancer. - A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ovarian Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Novartis AG - Samyang Corporation - Aphios Corporation - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - AntiCancer, Inc. - Merck KGaA - Access Pharmaceuticals, Inc. - Advaxis, Inc. - Innocell Corporation - PharmaGap Inc. - TRION Pharma GmbH - Advantagene, Inc. - BioNumerik Pharmaceuticals, Inc. - Alethia Biotherapeutics Inc. - OnKor Pharmaceuticals, Inc. - Coronado Biosciences, Inc. - Cerulean Pharma, Inc. - Heat Biologics, Inc. - PepTx, Inc. - Mebiopharm Co., Ltd. - DEKK-TEC, Inc. - ISA Pharmaceuticals B.V. - TAU Therapeutics, LLC - Gradalis Inc. For more information visit http://www.researchandmarkets.com/research/2r...ian_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Filtration.com Now Carries Trion Air Bear(R) Furnace Filters
PRWeb - Wed Sep 18, 9:31AM CDT
Filtration.com, a premier indoor air quality online store is proud to announce the newest addition to their product line, Trion Air Bear(R) filters. Trion is an aftermarket media air filter that fits in models from Generalaire(R), Skuttle(R), Ultravation(R) and their own Trion air purification system - Trion Air Bear Cub Air Cleaner.
Peritoneal Cancer - Pipeline Review, H2 2013 Report will Assist you in Planning Mergers and Acquisitions Effectively by Identifying Players of the Most Promising Pipeline
M2 - Mon Aug 12, 10:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zgbb5m/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Peritoneal Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peritoneal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peritoneal Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Peritoneal Cancer. - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Peritoneal Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: AstraZeneca PLC GlaxoSmithKline plc Oxford BioMedica plc Millennium Pharmaceuticals, Inc. Novartis AG Bayer AG Incyte Corporation EntreMed, Inc. Oncolytics Biotech Inc. Synta Pharmaceuticals Corp. Oasmia Pharmaceutical AB Spectrum Pharmaceuticals, Inc. Acceleron Pharma, Inc. TRION Pharma GmbH TetraLogic Pharmaceuticals CritiTech, Inc. ImmunoVaccine Technologies Inc. VentiRx Pharmaceuticals, Inc. Genelux Corporation For more information visit http://www.researchandmarkets.com/research/zg...eal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Fallopian Tube Cancer - Pipeline Review, H2 2013: Plan Mergers and Acquisitions Effectively By Identifying Players
M2 - Fri Aug 09, 6:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7fs44g/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Fallopian Tube Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer. Scope - A snapshot of the global therapeutic scenario for Fallopian Tube Cancer. - A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fallopian Tube Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 - Acceleron Pharma, Inc. - Amgen Inc. - AstraZeneca PLC - Boehringer Ingelheim GmbH - Cell Therapeutics, Inc. - Daiichi Sankyo Company, Ltd - Eli Lilly and Company - EntreMed, Inc. - GlaxoSmithKline plc - ImmunoVaccine Technologies Inc. - Incyte Corporation - Marshall Edwards, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - Oncolytics Biotech Inc. - Oxford BioMedica plc - RECEPTA Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRACON Pharmaceuticals, Inc. - TRION Pharma GmbH - TetraLogic Pharmaceuticals - VentiRx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/7f...lopian_tub About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epithelial Ovarian Cancer - Latest Pipeline Review Report
M2 - Wed Aug 07, 8:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/62k5jl/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H2 2013" report to their offering. 'Epithelial Ovarian Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epithelial Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer. Scope - A snapshot of the global therapeutic scenario for Epithelial Ovarian Cancer. - A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epithelial Ovarian Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Epithelial Ovarian Cancer Therapeutics Development - Boehringer Ingelheim GmbH - Amgen Inc. - AstraZeneca PLC - Oxford BioMedica plc - Novartis AG - Astellas Pharma Inc. - Bayer AG - Prima BioMed Limited - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - TRION Pharma GmbH - BioNumerik Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - RECEPTA Biopharma S.A. Drug Profiles - trebananib - sorafenib tosylate - elesclomol - paclitaxel - TroVax - MEK-162 - nintedanib - catumaxomab - CVac - VTX-2337 - levonorgestrel - plevitrexed - RebmAb-100 - cositecan - EGEN-001 - NY-ESO-1 Overlapping Peptides Vaccine - Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - HER-2/Neu Specific T Cells - MV-NIS Vaccine - pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine - Globo-H-GM2-sTn-TF-Tn-KLH Conjugate [QS-21] - DCVAC/OvCa For more information visit http://www.researchandmarkets.com/research/62k5jl/epithelial
Trion(R) Introduces a Motorized Air Damper for the Residential Market
PRWeb - Tue Aug 06, 8:07AM CDT
Trion(R), an innovative, international company dedicated to providing quality products for the commercial, industrial, and residential markets since 1947, is proud to introduce the latest product offering in residential indoor air quality. The Trion Motorized Damper (TMD520) is designed to introduce fresh air into the building envelope through an intake damper that is controlled by the microprocessor-based ventilation control interface. The system controls the amount of outdoor ventilation, promoting healthier indoor air quality, required by the Ventilation and Air Quality Standard defined in ASHRAE 62.2. This standard defines the roles of, and minimum requirements for, mechanical and natural ventilation systems and the building envelope intended to provide acceptable indoor air quality (IAQ) in low-rise residential buildings.
Game Industry Veteran Robin Kaminsky Joins Trion Worlds' Board of Directors
Business Wire - Thu Jul 11, 12:02PM CDT
Trion Worlds, global developer and publisher of premium online games, has brought technology, video games and entertainment executive Robin Kaminsky onto the company's Board of Directors.
Trion(R) Introduces the Latest Solution in Commercial Kitchen Air Cleaning
PRWeb - Thu May 16, 7:05AM CDT
Trion(R), an innovative, international company dedicated to providing quality indoor air quality products for the commercial, industrial, and residential markets since 1947, is proud to introduce the latest innovation in commercial indoor air quality. The Grease Viper(TM) Commercial Kitchen Air Cleaner is designed to treat grease, smoke, and odor emissions from exhaust ducts on commercial cooking applications.
Defiance(TM) Launches Worldwide Today
Business Wire - Tue Apr 02, 10:00AM CDT
Trion Worlds, the leading publisher and developer of premium games for the connected era, is proud to announce the launch of Defiance(TM), the groundbreaking futuristic online open world shooter for the Xbox 360(R) video game and entertainment system, the PlayStation(R)3 computer entertainment system and Windows PC. The Defiance Universe expands even further on April 15th, with the premiere of Syfy Network's Defiance series.
Trion Worlds and XLGAMES Team up to Bring Highly Anticipated ArcheAge(R) to Western Markets
Business Wire - Thu Jan 24, 12:00PM CST
Leading online games company Trion Worlds and renowned South Korea-based game developer XLGAMES have entered into a strategic agreement for Trion to exclusively publish and operate ArcheAge(R) in the West. Created by Jake Song, best known for his hit game Lineage, the highly anticipated ArcheAge is poised to be the most polished massively multiplayer online role-playing game (MMORPG) coming out of Asia. Trion will host the game on its Red Door platform in North America, Europe, Turkey, Australia and New Zealand.
(0)
(0)ALL THINGS MOBILE ANALYTIC INC. (ATMH) Stock Research Links
Scroll down for more posts ▼